IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

PROFIT ALERT
REDUCTION IN LOSS

This announcement is made by IMPACT Therapeutics, Inc (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the Board's preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 (the "**Relevant Period**"), and the information currently available to the Board, the Group expects to record for the Relevant Period:

- revenue of approximately RMB94.7 million to RMB115.7 million, representing an increase of approximately 276% to 359% as compared with approximately RMB25.2 million for the six months ended June 30, 2025 (the "**Corresponding Period**");

- a loss for the period of approximately RMB81.7 million to RMB99.9 million, representing a decrease of approximately 37% to 22% as compared with approximately RMB128.7 million for the Corresponding Period.

The expected changes set out above were primarily attributable to: (i) an increase in revenue, driven by the accelerated commercialization of senaparib following its inclusion in the National Reimbursement Drug List in early 2026, which has significantly expanded patient access and driven substantial volume growth; (ii) the licensing revenue recognized during the Relevant Period, which was derived from a milestone payment received under the collaboration agreement with Eikon Therapeutics, Inc. relating to IMP1734 and other PARP1-selective inhibitors, resulting from IMP1734's advancement into Phase II clinical trials; and (iii) a decrease in interest from redemption liabilities on ordinary shares, as a result of the termination of the redemption liabilities on ordinary shares of the Company (which is one-off in nature), narrowing the loss.

The information contained in this announcement is a preliminary assessment made by the Board based on the unaudited consolidated management accounts of the Group and the information currently available to the Board. It has not been audited or reviewed by the Company's auditor or by the audit committee of the Board and does not constitute a profit forecast. The Company expects to publish its interim results announcement for the Relevant Period in August 2026, and Shareholders and potential investors are advised to read it carefully when it is published.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, August 11, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.